Pfizer · NSE: PFIZER · BSE: 500680
Q1 FY25 results · Apr–Jun 2024
Pfizer reported revenue from operations of ₹562.86 crore (up 5.9% from Q1 FY24) and net profit of ₹150.71 crore (up 61.1% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a standalone basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 562.86 | 531.36 | +5.9% | 546.63 | +3.0% |
| Other income | 41.84 | 33.46 | +25.0% | 75.13 | −44.3% |
| Total income | 604.70 | 564.82 | +7.1% | 621.76 | −2.7% |
| Profit before tax | 202.62 | 125.75 | +61.1% | 243.86 | −16.9% |
| Net profit for the period | 150.71 | 93.53 | +61.1% | 178.86 | −15.7% |
| EPS, basic (₹) | 32.94 | 20.44 | +61.2% | 22.33 | +47.5% |
| Net margin (%) | 26.8 | 17.6 | 32.7 |
Standalone
- Filed with BSE
- 30 Jul 2024, 17:07 IST
- Board meeting
- 29 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE